Cigna Corp. and Aetna Inc. have reached agreements for heart drug Entresto with Swiss drugmaker Novartis AG that tie pricing to patient outcomes.
Such pay-for-performance deals, which set pricing on certain drugs based on how well they work for certain patients, have been spurred by concerns about increasingly high prices for some medicines.
Health insurer Cigna said in a news release Monday said its pay-for-performance deal with Novartis for Entresto primarily links the financial terms to a reduction in the portion of its customers that are hospitalized for heart failure.
Brief understanding of Pay-for-Performance drug performance model?
click here to learn